Biocon Biologics gets US FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market
==========

Biocon Biologics has received approval from the US Food and Drug Administration (US FDA) for its biosimilar aflibercept Yesafili, allowing the company to enter the US ophthalmology market. The approval marks Biocon Biologics' entry into the therapeutic area of ophthalmology in the United States. The company had previously received approvals for the biosimilar aflibercept in Europe and the United Kingdom. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor used to treat various ophthalmology conditions. The sales of aflibercept in the US were approximately $5.89 billion in 2023.

#BioconBiologics #UsFda #BiosimilarAfliberceptYesafili #UsOphthalmologyMarket

https://timesofindia.indiatimes.com/business/international-business/biocon-biologics-gets-us-fda-approval-for-biosimilar-aflibercept-yesafili-enters-us-ophthalmology-market/articleshow/110289706.cms